| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Ofranergene obadenovec | VB-111; GT-111 | Phase 3 Clinical | Vascular Pharmaceuticals Inc | Ovarian Neoplasms; Thyroid Carcinoma, Anaplastic; Neoplasms; Glioblastoma; Neuroendocrine Tumors; Colorectal Neoplasms | Details |
| Atrosab | Phase 1 Clinical | Celonic | Inflammation | Details |

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland



